HUP0104372A2 - Stabil amorf amifosztin készítmények, eljárások előállításukra és alkalmazásuk - Google Patents

Stabil amorf amifosztin készítmények, eljárások előállításukra és alkalmazásuk

Info

Publication number
HUP0104372A2
HUP0104372A2 HU0104372A HUP0104372A HUP0104372A2 HU P0104372 A2 HUP0104372 A2 HU P0104372A2 HU 0104372 A HU0104372 A HU 0104372A HU P0104372 A HUP0104372 A HU P0104372A HU P0104372 A2 HUP0104372 A2 HU P0104372A2
Authority
HU
Hungary
Prior art keywords
preparation
methods
same
stable
stable amorphous
Prior art date
Application number
HU0104372A
Other languages
English (en)
Inventor
Martin Stogniew
Javad M. Zadei
Original Assignee
Medimmune Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Oncology, Inc. filed Critical Medimmune Oncology, Inc.
Publication of HUP0104372A2 publication Critical patent/HUP0104372A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A jelen tal lm ny az amorf aminoalkil-dihidrogénfoszforotio tok,főként az amifosztin steril, stabil, szil rd form ból visszaoldható ésa betegnek parenter lisan alkalmazható gyógyszerkészítményeirevonatkozik. Vonatkozik tov bb ezen készítmények elő llít si elj r s rais, amely elj r s sor n a jelenleg létező v kuumsz rított, amorfamifosztin készítményekhez képest javított hőstabilit ssal rendelkezőgyógyszerkészítményt kapunk. A hőstabil amorf amifosztingyógyszerkészítmény gyógyszerészetileg elfogadható stabiliz lószereketés segédanyagokat egyar nt tartalmazhat. Ó
HU0104372A 1998-11-16 1999-11-15 Stabil amorf amifosztin készítmények, eljárások előállításukra és alkalmazásuk HUP0104372A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/192,933 US6407278B2 (en) 1998-11-16 1998-11-16 Stable amorphous amifostine compositions and methods for the preparation and use of the same
PCT/US1999/027050 WO2000029025A1 (en) 1998-11-16 1999-11-15 Stable amorphous amifostine compositions and methods for the preparation and use of same

Publications (1)

Publication Number Publication Date
HUP0104372A2 true HUP0104372A2 (hu) 2002-04-29

Family

ID=22711626

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104372A HUP0104372A2 (hu) 1998-11-16 1999-11-15 Stabil amorf amifosztin készítmények, eljárások előállításukra és alkalmazásuk

Country Status (16)

Country Link
US (1) US6407278B2 (hu)
EP (1) EP1131103A1 (hu)
JP (1) JP4703854B2 (hu)
KR (1) KR20010101015A (hu)
CN (1) CN1195549C (hu)
AU (1) AU1725500A (hu)
BR (1) BR9915379A (hu)
CA (1) CA2350815C (hu)
CZ (1) CZ20011722A3 (hu)
HK (1) HK1041639B (hu)
HU (1) HUP0104372A2 (hu)
ID (1) ID30238A (hu)
MX (1) MXPA01004867A (hu)
PL (1) PL347691A1 (hu)
SK (1) SK6672001A3 (hu)
WO (1) WO2000029025A1 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DE10043170C2 (de) * 2000-09-01 2002-10-24 Klinge Co Chem Pharm Fab Amifostin-Monohydrat und Verfahren zu seiner Herstellung
NZ534598A (en) * 2002-02-01 2004-11-26 Shimoda Biotech Pty Ltd Pharmaceutical composition
US7629333B2 (en) * 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
US20030215394A1 (en) * 2002-05-17 2003-11-20 Short Robert E. Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
ES2360064T3 (es) 2003-11-14 2011-05-31 Ajinomoto Co., Inc. Dispersión sólida o preparación de dispersión sólida medicinal de un derivado de fenilalanina.
JP4526838B2 (ja) * 2004-03-04 2010-08-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 配合適性試験用試料の調製方法及びそれに用いるキット
CA2584138A1 (en) * 2004-10-18 2006-04-27 Raphael C. Lee Methods and compositions for treatment of free radical injury
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8133513B2 (en) 2006-03-23 2012-03-13 Shionogi & Co., Ltd. Solid preparation having improved solubility
US8815833B2 (en) * 2006-11-09 2014-08-26 Seidose, LLC Stable amifostine liquid concentrate
US20080253997A1 (en) * 2007-03-27 2008-10-16 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
US20100240711A1 (en) 2007-09-21 2010-09-23 Shionogi & Co., Ltd. Solid preparation comprising npyy5 receptor antagonist
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
JP5563528B2 (ja) * 2010-06-29 2014-07-30 高田製薬株式会社 ニコチン酸アミドを含有するゲムシタビン凍結乾燥製剤
CN102286019B (zh) * 2011-07-11 2014-02-05 大连美罗大药厂 二水合3-氨基丙基胺乙基硫代磷酸的制备方法
CN104744478B (zh) * 2015-03-20 2016-08-24 中国人民解放军第二军医大学 一种防治辐射损伤的化合物、单晶及其制备方法和应用
EP3330251A1 (en) * 2016-11-30 2018-06-06 Clevexel Pharma Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol
BR112021006288A2 (pt) * 2018-10-01 2021-07-06 Wintermute Biomedical Inc composição terapêutica, e, métodos para tratar um paciente e para tratar câncer.
CN110755373B (zh) * 2019-11-18 2020-09-08 扬子江药业集团广州海瑞药业有限公司 一种盐酸法舒地尔注射液药物组合物及制备方法
CN116283682B (zh) * 2023-02-21 2024-08-02 梯尔希（南京）药物研发有限公司 一种同位素标记的氨磷汀代谢物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
JPS6041676B2 (ja) 1977-09-21 1985-09-18 山之内製薬株式会社 Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
US4424216A (en) 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en) * 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
CA2250570A1 (en) * 1996-03-26 1997-10-02 Eli Lilly And Company Formulations of ob protein
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6537561B1 (en) * 1997-02-27 2003-03-25 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration

Also Published As

Publication number Publication date
PL347691A1 (en) 2002-04-22
BR9915379A (pt) 2002-01-15
HK1041639A1 (en) 2002-07-19
MXPA01004867A (es) 2003-07-21
WO2000029025A1 (en) 2000-05-25
CA2350815C (en) 2008-10-07
US6407278B2 (en) 2002-06-18
JP2002529519A (ja) 2002-09-10
CN1195549C (zh) 2005-04-06
CZ20011722A3 (cs) 2001-10-17
JP4703854B2 (ja) 2011-06-15
KR20010101015A (ko) 2001-11-14
HK1041639B (zh) 2005-09-30
AU1725500A (en) 2000-06-05
SK6672001A3 (en) 2001-11-06
US20020010357A1 (en) 2002-01-24
CN1333694A (zh) 2002-01-30
EP1131103A1 (en) 2001-09-12
ID30238A (id) 2001-11-15
CA2350815A1 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
HUP0104372A2 (hu) Stabil amorf amifosztin készítmények, eljárások előállításukra és alkalmazásuk
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
HUP0500558A2 (hu) Alacsony dózisú entecavir formuláció és eljárás előállítására
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
BR0113666A (pt) Inibidores da protease peptidomimética
HUP0202537A2 (hu) Vakcinakészítmény és eljárás annak alkalmazására
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
HUP0301349A2 (hu) IL-11-tartalmú készítmények
HUP0302897A2 (hu) Kiváló hatású transzdermális terápiás készítmény a Parkinson-kór kezelésére
CA2204277A1 (en) Combined meningitis vaccine
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
HUP9904075A2 (hu) Loratidint és egy decongestanst tartalmazó készítmény asztma kezelésére
WO1999061014A3 (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
EP1023901A4 (en) MEDICINES FOR HEPATITIS C AND THE USE THEREOF
PL353470A1 (en) Formulations of steroid solutions for inhalatory administration
SE0102887D0 (sv) New formulation
EP0238198A3 (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein
HU230002B1 (en) Use of l-carnitine for preparation of compositions for stabilizing the proteins
SG46425A1 (en) Arginine derivatives
DK248987A (da) Farmaceutiske praeparater til forbedring af sammensaetningen af lipider i blod
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
HUP0302371A2 (hu) Béta-blokkolót és adott esetben koleszterinszint-csökkentőt tartalmazó új gyógyszerkészítmény
MD1135F1 (en) Paradontium treatment method